Vikram Mehra, MD
Psychiatry · Katy, TXNPI 1801848957
Payments from drug & device makers
Across 2,594 payments — averaging $462.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$564K
- Teva Pharmaceuticals USA, Inc.$146K
- E.r. Squibb & Sons, L.L.C.$140K
- Vanda Pharmaceuticals Inc.$96K
- Otsuka America Pharmaceutical, Inc.$94K
- Sunovion Pharmaceuticals Inc.$41K
- plus $118K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 845 | $564,493 |
| Teva Pharmaceuticals USA, Inc. | 310 | $145,867 |
| E.r. Squibb & Sons, L.L.C. | 211 | $140,078 |
| Vanda Pharmaceuticals Inc. | 207 | $95,854 |
| Otsuka America Pharmaceutical, Inc. | 266 | $94,198 |
| Sunovion Pharmaceuticals Inc. | 154 | $41,359 |
| Axsome Therapeutics, Inc. | 59 | $39,563 |
| Supernus Pharmaceuticals, Inc. | 77 | $34,848 |
| Neurocrine Biosciences, Inc. | 62 | $26,754 |
| Corium, LLC | 44 | $4,385 |
| AbbVie(2 entities) | 110 | $3,306 |
| Indivior Inc. | 40 | $2,507 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $1,887 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,620 |
| Lundbeck LLC | 64 | $1,299 |
| Johnson & Johnson | 24 | $554 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $356 |
| Eisai Inc. | 29 | $273 |
| Almatica Pharma LLC | 6 | $118 |
| Bausch Health US, LLC | 6 | $106 |
| Idorsia Pharmaceuticals US Inc | 6 | $105 |
| Avanir Pharmaceuticals, Inc. | 4 | $81 |
| Livanova USA, Inc. | 1 | $21 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
How this compares
$1,199,671 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Katy
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.